CytomX Therapeutics CTMX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's operating lease liabilities (current)?
- CytomX Therapeutics (CTMX) reported operating lease liabilities (current) of $2.86M in Q1 2026.
- How has CytomX Therapeutics's operating lease liabilities (current) changed year-over-year?
- CytomX Therapeutics's operating lease liabilities (current) decreased by 46.0% year-over-year, from $5.29M to $2.86M.
- What is the long-term trend for CytomX Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), CytomX Therapeutics's operating lease liabilities (current) has grown at a 5.8% compound annual growth rate (CAGR), from $3.2M to $4.24M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.